Abbott Laboratories $ABT Holdings Lowered by S&CO Inc.

Key Points

• S&CO Inc. cut its Abbott Laboratories stake by 6.6% in the second quarter, selling 13,199 shares and retaining 186,521 shares valued at approximately $16.9 million. Institutional investors collectively own 75.18% of Abbott’s outstanding stock.
• Abbott reported quarterly revenue of $12.59 billion and adjusted earnings of $1.31 per share, exceeding analyst estimates, while revenue increased 13% year over year. The company issued full-year 2026 EPS guidance of $5.45 to $5.60 and pays an annualized dividend of $2.52 per share.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $119.50 price target. Recent catalysts include FDA authorization of Abbott’s Libre Duo glucose-and-ketone monitor, although the company also faces legal risks tied to a $670 million infant-formula settlement.

S&CO Inc. lowered its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 6.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,521 shares of the healthcare product maker's stock after selling 13,199 shares during the quarter. Abbott Laboratories makes up 1.0% of S&CO Inc.'s investment portfolio, making the stock its 28th largest holding. S&CO Inc.'s holdings in Abbott Laboratories were worth $16,924,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its holdings in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock worth $10,004,880,000 after buying an additional 1,627,791 shares during the period. Capital International Investors raised its holdings in shares of Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares during the period. J. Stern & Co. LLP lifted its position in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Capital Research Global Investors boosted its stake in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the period. Finally, Norges Bank purchased a new position in Abbott Laboratories during the 4th quarter worth approximately $2,938,892,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article
• Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report
• Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ABT. Royal Bank Of Canada restated an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. BTIG Research increased their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. Finally, Wells Fargo & Company upped their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Trading Down 1.7%

NYSE ABT opened at $114.11 on Thursday. The company has a market capitalization of $197.45 billion, a PE ratio of 36.93, a price-to-earnings-growth ratio of 2.25 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm's fifty day simple moving average is $101.66 and its 200-day simple moving average is $100.13.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. The business's quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source